HK1137660A1 - Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof - Google Patents
Tosylate salt of a therapeutic compound and pharmaceutical compositions thereofInfo
- Publication number
- HK1137660A1 HK1137660A1 HK10102903.0A HK10102903A HK1137660A1 HK 1137660 A1 HK1137660 A1 HK 1137660A1 HK 10102903 A HK10102903 A HK 10102903A HK 1137660 A1 HK1137660 A1 HK 1137660A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical compositions
- therapeutic compound
- tosylate salt
- tosylate
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88593107P | 2007-01-22 | 2007-01-22 | |
PCT/IB2008/000088 WO2008090429A1 (en) | 2007-01-22 | 2008-01-10 | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1137660A1 true HK1137660A1 (en) | 2010-08-06 |
Family
ID=39277093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102903.0A HK1137660A1 (en) | 2007-01-22 | 2010-03-19 | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
Country Status (25)
Country | Link |
---|---|
US (1) | US8314139B2 (zh) |
EP (1) | EP2124933B1 (zh) |
JP (1) | JP4585610B2 (zh) |
KR (1) | KR101108109B1 (zh) |
CN (1) | CN101631545B (zh) |
AR (1) | AR064963A1 (zh) |
AU (1) | AU2008208653B2 (zh) |
BR (1) | BRPI0806473A2 (zh) |
CA (1) | CA2676456C (zh) |
CL (1) | CL2008000180A1 (zh) |
DK (1) | DK2124933T3 (zh) |
ES (1) | ES2395744T3 (zh) |
HK (1) | HK1137660A1 (zh) |
IL (1) | IL199587A (zh) |
MX (1) | MX2009007782A (zh) |
NZ (1) | NZ577951A (zh) |
PE (1) | PE20081690A1 (zh) |
PL (1) | PL2124933T3 (zh) |
PT (1) | PT2124933E (zh) |
RU (1) | RU2430099C2 (zh) |
SI (1) | SI2124933T1 (zh) |
TW (1) | TWI358294B (zh) |
UY (1) | UY30878A1 (zh) |
WO (1) | WO2008090429A1 (zh) |
ZA (1) | ZA200905827B (zh) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
MX2008016343A (es) * | 2006-06-23 | 2009-01-19 | Abbott Lab | Derivados ciclopropil amina como moduladores del receptro de histamina h3. |
RU2451016C2 (ru) | 2007-12-07 | 2012-05-20 | Пфайзер Инк. | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида |
US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
ES2426539B1 (es) * | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2867236B1 (en) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP6505023B2 (ja) | 2013-02-19 | 2019-04-24 | ファイザー・インク | Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 |
CA2925743C (en) | 2013-10-04 | 2018-03-06 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
CA2944308A1 (en) | 2014-04-01 | 2015-10-08 | Pfizer Inc. | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
AU2015245260A1 (en) | 2014-04-10 | 2016-10-06 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides |
EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
MX2017001565A (es) | 2014-08-06 | 2017-04-27 | Pfizer | Compuestos de imidazopiridazina. |
EA033423B1 (ru) | 2015-02-03 | 2019-10-31 | Pfizer | Циклопропанбензофуранилпиридопиразиндионы |
HUE059372T2 (hu) | 2015-06-17 | 2022-11-28 | Pfizer | Triciklusos vegyületek és azok alkalmazása foszfodiészteráz inhibitorként |
WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
BR112018003489A2 (pt) | 2015-09-24 | 2018-09-25 | Pfizer | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
PL3419979T3 (pl) | 2016-02-23 | 2020-06-29 | Pfizer Inc. | Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe |
WO2018002760A1 (en) | 2016-07-01 | 2018-01-04 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
IL269215B (en) | 2017-03-10 | 2022-09-01 | Pfizer | Disubstituted imidazole[4,5-c]quinoline derivatives |
BR112019018688A2 (pt) | 2017-03-10 | 2020-04-07 | Pfizer | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 |
CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
CN110944998B (zh) | 2017-06-22 | 2022-08-16 | 辉瑞大药厂 | 二氢-吡咯并-吡啶衍生物 |
AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
DK3768669T3 (da) | 2018-03-23 | 2023-04-24 | Pfizer | Piperazinazaspiroderivater |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2007519707A (ja) * | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | ヒスタミン−3受容体モジュレーター |
US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
RU2451016C2 (ru) | 2007-12-07 | 2012-05-20 | Пфайзер Инк. | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида |
-
2008
- 2008-01-10 JP JP2009546829A patent/JP4585610B2/ja not_active Expired - Fee Related
- 2008-01-10 DK DK08702250.5T patent/DK2124933T3/da active
- 2008-01-10 PL PL08702250T patent/PL2124933T3/pl unknown
- 2008-01-10 CN CN2008800028688A patent/CN101631545B/zh not_active Expired - Fee Related
- 2008-01-10 KR KR1020097015310A patent/KR101108109B1/ko not_active IP Right Cessation
- 2008-01-10 MX MX2009007782A patent/MX2009007782A/es active IP Right Grant
- 2008-01-10 WO PCT/IB2008/000088 patent/WO2008090429A1/en active Application Filing
- 2008-01-10 NZ NZ577951A patent/NZ577951A/en not_active IP Right Cessation
- 2008-01-10 CA CA2676456A patent/CA2676456C/en not_active Expired - Fee Related
- 2008-01-10 SI SI200830802T patent/SI2124933T1/sl unknown
- 2008-01-10 ES ES08702250T patent/ES2395744T3/es active Active
- 2008-01-10 EP EP08702250A patent/EP2124933B1/en not_active Not-in-force
- 2008-01-10 RU RU2009124541/04A patent/RU2430099C2/ru not_active IP Right Cessation
- 2008-01-10 BR BRPI0806473-3A patent/BRPI0806473A2/pt not_active IP Right Cessation
- 2008-01-10 PT PT87022505T patent/PT2124933E/pt unknown
- 2008-01-10 AU AU2008208653A patent/AU2008208653B2/en not_active Ceased
- 2008-01-18 US US12/016,521 patent/US8314139B2/en not_active Expired - Fee Related
- 2008-01-18 AR ARP080100236A patent/AR064963A1/es unknown
- 2008-01-21 TW TW097102227A patent/TWI358294B/zh not_active IP Right Cessation
- 2008-01-21 UY UY030878A patent/UY30878A1/es not_active Application Discontinuation
- 2008-01-21 PE PE2008000164A patent/PE20081690A1/es not_active Application Discontinuation
- 2008-01-22 CL CL200800180A patent/CL2008000180A1/es unknown
-
2009
- 2009-06-25 IL IL199587A patent/IL199587A/en not_active IP Right Cessation
- 2009-08-21 ZA ZA200905827A patent/ZA200905827B/xx unknown
-
2010
- 2010-03-19 HK HK10102903.0A patent/HK1137660A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1137660A1 (en) | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof | |
ZA200900347B (en) | Preparation of pharmaceutical compositions | |
IL199853A (en) | Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them | |
EP2150109A4 (en) | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | |
IL289165B2 (en) | Modified azole-dione compounds and pharmaceutical preparations containing them | |
IL195237A0 (en) | Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same | |
EP2291157A4 (en) | COMPOSITIONS AND METHODS FOR TRANSDERING DELIVERY OF PHARMACEUTICAL COMPOUNDS | |
EP2168944A4 (en) | AMIN CONNECTION AND ITS PHARMACEUTICAL USE | |
ZA201002547B (en) | Heterocyclic compound and pharmaceutical composition thereof | |
AP2627A (en) | New form of administration of racecadotril | |
AP3542A (en) | Anti-malarial pharmaceutical composition | |
HK1181389A1 (zh) | 包含酰胺衍生物或其可藥用鹽的藥物組合物 | |
PL2121025T3 (pl) | Sposoby i kompozycje dla dostarczania czynnika terapeutycznego | |
EP2114374A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE | |
GB0716907D0 (en) | Pharmaceutical powder compositions | |
GB0623897D0 (en) | Pharmaceutical composition of memantine | |
IL202766A0 (en) | Pharmaceutical combination of opioid and prostaglandin compound | |
PL2195006T3 (pl) | Zastosowanie analogu bifaliny jako przeciwbólowego środka farmaceutycznego | |
HUP0700096A2 (en) | Homeopathic pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170110 |